KZIA Kazia Therapeutics Limited: Earnings per share for the last 12 months

Kazia (KZIA) - corporate logo

The global scaling potential of Kazia Therapeutics (KZIA) relies on oncology patents, where low molecule production costs are transitioning from the trial stage. The process is being accelerated by cloud AI for data analysis, as confirmed by the current EPS YoY TTM trend, where the current parameter equals 76.80. Meanwhile, the company adheres to environmental bio-waste disposal regulations, minimizing its climate impact.

Kazia (KZIA) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/18/2026

KZIA (Kazia): analytical breakdowns and indicator data

- company stock capitalization data:
Fundamental company valuation:KZIA Kazia Therapeutics
Flagship merchandise of Kazia Therapeutics Ltd

This indicator measures the percentage change in rolling annual earnings per share, neutralizing reporting seasonality. It allows investors to filter out speculative noise by relying on the actual profitability dynamics of the business. An analysis of the annual TTM net income per share trend confirms the stability of fundamental indicators. This is critical for Kazia Therapeutics (KZIA), as the company minimizes costs through the outsourcing of cancer clinical trials. Effective coordination of external vendors directly impacts the final profitability.

Direct competitors

Net earnings per one share for the last twelve months Incyte Corp|HCM: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NUVB|DAWN (dayonebio.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months monopartx.com (MNPR)|Earnings per share for the last twelve months Inhibrx Corp (INBX)|IMAB - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Fennec Pharmaceuticals Inc FENC|Heron Therapeutics - Earnings per share for the last twelve months|NVCT - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months coherus.com|CRBP: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Cardiff Oncology, Inc. CRDF|Net earnings per share for the last 12 months BYSI|Net earnings per one share for the last twelve months BioAtla BCAB|Net earnings per share for the last 12 months LIXT (Lixte Biotechnology)|CTXR (Citius Pharma) - Earnings per share for the trailing year|Cellectar Biosciences - Net earnings per share for the last 12 months|Earnings per share for the last four quarters BLRX (BioLineRx)|Can-Fite BioPharma, Ltd. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year APRE (aprea.com)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana Corp (NCNA)|Earnings per share for the last twelve months Chimerix|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Corporation (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Therapeutics, Inc.) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months